D.R. Horton, Inc. Announces Dual Listing on NYSE Texas
ARLINGTON, Texas--(BUSINESS WIRE)-- D.R. Horton, Inc. (NYSE:DHI), America's Builder, announced today the dual listing of its common stock on NYSE Texas, the newly launched fully electronic equities exchange headquartered in Dallas, TX. The Company will maintain its primary listing on the New York Stock Exchange and trade with the same 'DHI' ticker symbol on NYSE Texas.
David Auld, Chairman of the Board, said, 'We are pleased to be a Founding Member of NYSE Texas and show our support to the state we have called home for nearly fifty years. We believe Texas's long-standing commitment to pro-growth, business-friendly policies promotes a resilient economy. As the Lone Star State's economy continues to thrive and build momentum, we are committed to contributing in a meaningful way by providing housing to the rapidly growing population of Texas.'
'Based in Texas, D.R. Horton has been the largest homebuilder by volume in the United States for over two decades,' said Chris Taylor, Chief Development Officer, NYSE Group. 'We are proud to welcome the Company to NYSE Texas as a Founding Member.'
About D.R. Horton, Inc.
D.R. Horton, Inc., America's Builder, has been the largest homebuilder by volume in the United States since 2002 and has closed more than 1,100,000 homes in its 46-year history. D.R. Horton has operations in 126 markets in 36 states across the United States and is engaged in the construction and sale of high-quality homes through its diverse product portfolio with sales prices generally ranging from $250,000 to over $1,000,000. The Company also constructs and sells both single-family and multi-family rental properties. During the twelve-month period ended March 31, 2025, D.R. Horton closed 86,137 homes in its homebuilding operations, in addition to 3,312 single-family rental homes and 2,282 multi-family rental units in its rental operations. D.R. Horton also provides mortgage financing, title services and insurance agency services for its homebuyers and is the majority-owner of Forestar Group Inc., a publicly traded national residential lot development company.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025
NEW YORK, June 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of May 31, 2025, an increase of $1.1 billion from assets under management of $87.5 billion at April 30, 2025. The increase was due to market appreciation of $1.3 billion, partially offset by distributions of $150 million and net outflows of $88 million. Assets Under Management (unaudited) ($ in millions) AUM Net MarketAUM By investment vehicle: 4/30/2025 Flows App/(Dep) Distributions 5/31/2025 Institutional Accounts: Advisory $19,937 $10 $352 - $20,299 Subadvisory 14,091 (19) 306 (57) 14,321 Total Institutional Accounts 34,028 (9) 658 (57) 34,620 Open-end Funds 42,210 (80) 510 (42) 42,598 Closed-end Funds 11,271 1 176 (51) 11,397 Total AUM $87,509 ($88) $1,344 ($150) $88,615 About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore. View original content: SOURCE Cohen & Steers, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Calavo (NASDAQ:CVGW) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops 15.3%
Fresh produce company Calavo Growers (NASDAQ:CVGW) fell short of the market's revenue expectations in Q1 CY2025 as sales rose 3.3% year on year to $190.5 million. Its non-GAAP profit of $0.40 per share was 25% below analysts' consensus estimates. Is now the time to buy Calavo? Find out in our full research report. Revenue: $190.5 million vs analyst estimates of $192.8 million (3.3% year-on-year growth, 1.1% miss) Adjusted EPS: $0.40 vs analyst expectations of $0.53 (25% miss) Adjusted EBITDA: $11.4 million vs analyst estimates of $14.74 million (6% margin, 22.7% miss) Operating Margin: 4%, in line with the same quarter last year Market Capitalization: $493.7 million 'Our second fiscal quarter performance reflects the strength of our commercial strategy and disciplined operational execution amid continued volatility in the avocado market. Revenue grew year-over-year, driven by strong pricing performance,' said Lee Cole, President and Chief Executive Officer of Calavo Growers, Inc. A trailblazer in the avocado industry, Calavo Growers (NASDAQ:CVGW) is a pioneering California-based provider of high-quality avocados and other fresh food products. A company's long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. With $694.5 million in revenue over the past 12 months, Calavo is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers. As you can see below, Calavo's demand was weak over the last three years. Its sales fell by 15.8% annually, a tough starting point for our analysis. This quarter, Calavo's revenue grew by 3.3% year on year to $190.5 million, falling short of Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to decline by 1.8% over the next 12 months. it's tough to feel optimistic about a company facing demand difficulties. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. If you've followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills. Calavo broke even from a free cash flow perspective over the last two years, giving the company limited opportunities to return capital to shareholders. We struggled to find many positives in these results as Calavo fell short of Wall Street's estimates across all key metrics. Overall, this quarter could have been better. The stock traded down 15.3% to $23.42 immediately after reporting. The latest quarter from Calavo's wasn't that good. One earnings report doesn't define a company's quality, though, so let's explore whether the stock is a buy at the current price. If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
24 minutes ago
- Business Upturn
MUSE Microscopy, Inc. Launches Veterinary Digital Pathology with the First-of-Its-Kind Tissue-to-Direct Digital Imaging for the Veterinary Market
IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) — MUSE Microscopy, Inc., a pioneer in digital pathology innovation, today announced the formation of MUSE Veterinary Digital Pathology, LLC, a wholly-owned subsidiary focused on transforming pathology through point-of-care service. This initiative aims to provide same-day results for tissue biopsies. This new service will provide the gold standard of patient care allowing veterinarians to deliver pet parents with diagnosis, prognosis, and treatment plans efficiently using the SmartPath MUSE Technology™ (SmartPath)* Platform. The strategic move signifies MUSE's formal entry into the veterinary health market, bringing point-of-care and real-time diagnostic imaging to specialty, emergency, and family veterinary practices nationwide. Utilizing the unique capabilities of SmartPath for rapid, non-destructive tissue imaging, MUSE Veterinary Digital Pathology empowers veterinarians to make real-time treatment decisions, marking a significant innovation in tissue pathology in the past century. Matthew Nunez, CEO of MUSE Microscopy, will lead MUSE Veterinary Digital Pathology supported by a seasoned executive, Darin Nelson, who has a proven track record in building and scaling veterinary diagnostic companies. He acquired more than 800 animal hospitals for both VCA and Thrive Pet Healthcare and helped pet insurer Trupanion go public. Darin will join the company as President. Dr. Jeffrey Edwards, DVM, MPH, MRVCS, DAVCP, a clinical leader in veterinary diagnostics in his storied career, has been appointed as Chief Medical Officer overseeing the anatomic pathology team and the translational adoption of our innovative technology in veterinary practices nationwide.. Advertisement 'This launch represents a natural and strategic expansion of our technology platform,' stated Matthew Nunez. 'The veterinary sector is primed for innovation in diagnostic speed and precision. With MUSE Veterinary Digital Pathology, we are delivering state-of-the-art digital pathology directly to the point-of-care, empowering veterinarians to deliver faster diagnoses, reduce unnecessary delays, and elevate patient care.' MUSE Veterinary Digital Pathology will initially target specialty and emergency practices and large general practices, expected to commence in Q4 2025. The platform's intraoperative capabilities, same day results, and SmartPath's tissue-to-digital imaging will provide real-time surgical margin assessments and tissue diagnostics without reliance on current conventional slide-based workflows. 'This is about putting powerful diagnostic tools directly into the hands of veterinarians when and where they need them most,' stated Darin Nelson. 'Our goal is to enable faster decision-making, minimize wait times, and ultimately improve clinical outcomes for animal patients.' 'Veterinary medicine is long overdue for this level of innovation,' added Dr. Jeffrey Edwards. 'With our groundbreaking technology, we can reduce the delay in receiving biopsy results currently requiring couriers and 3-7 days down to same day diagnosis, changing the entire dynamic of medical management and clinical decision making as well as alleviated owner anxiety of waiting.' MUSE Veterinary Digital Pathology will operate independently while leveraging MUSE Microscopy's existing infrastructure, regulatory framework, personnel, and proprietary imaging technologies. The company anticipates additional announcements in the coming months, including pilot partnerships and distribution opportunities across the U.S. and internationally. About MUSE Microscopy, Inc. MUSE Microscopy is a company that specializes in the application of Microscopy with Ultraviolet Surface Excitation (MUSE). We have developed a MUSE-enabled imaging system for diagnostic assistance in pathology, and research applications. Our commercial product, SmartPath MUSE Technology™ (SmartPath)*, is a slide-free direct-to-digital imaging platform that aims to transform the patient's experience and provide healthcare professionals with quick diagnostic information through digital imaging. To learn more, you can visit their website at or find them on social media platforms such as Twitter, Facebook, and LinkedIn. *Pending FDA approval. Limits on Accuracy This press release is intended to provide information about MUSE Microscopy, Inc.'s research and potential product. Information is believed to be accurate at the time it is created. However, like any printed material, information may become outdated over time. Information may contain technical inaccuracies or typographical errors. Information may be changed or updated without notice. There may also be improvements or changes in the products and services described in this press release at any time without notice. It is important that you rely on the advice of an appropriate professional. Nothing contained in any presentation is to be construed as medical, legal, investment, financial, or other advice. This information is not intended to be a substitute for such advice. MUSE Microscopy, Inc., does not endorse any specific techniques or methods of treatment. Individuals are advised to consult their health care professionals for full information about the potential adverse reactions from use of the medical technologies discussed in this press release. We will use reasonable efforts to include accurate and up-to-date information on the website, but MUSE Microscopy, Inc. makes no warranties or representations as to its accuracy. Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans, prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. MEDIA CONTACT: Matthew Nuñez Tel: 949.813.6121 [email protected] Source: MUSE Microscopy, Inc. Join the Evolution. Embrace the Future. #DigitalPathology #SlideFreeRevolution #SmartPathMUSE For more information about MUSE Microscopy and its innovative technologies, please visit Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
